Geriatric factors analyses from FFCD 2001-02 phase III study of first-line chemotherapy for elderly metastatic colorectal cancer patients

被引:27
作者
Aparicio, Thomas [1 ]
Gargot, Dany [2 ]
Teillet, Laurent [3 ]
Maillard, Emilie [4 ]
Genet, Dominique [5 ]
Cretin, Jacques [6 ]
Locher, Christophe [7 ]
Bouche, Olivier [8 ]
Breysacher, Gilles [9 ]
Seitz, Jean-Francois [10 ]
Gasmi, Mohamed [11 ]
Stefani, Laetitia [12 ]
Ramdani, Mohamed [13 ]
Lecomte, Thierry [14 ]
Auby, Dominique [15 ]
Faroux, Roger [16 ]
Bachet, Jean-Baptiste [17 ]
Lepere, Celine [18 ]
Khemissa, Faiza [19 ]
Sobhani, Iradj [20 ]
Boulat, Olivier [21 ]
Mitry, Emmanuel [22 ]
Jouve, Jean-Louis [23 ,24 ]
机构
[1] Univ Paris 07, CHU St Louis, APHP, Gastroenterol Dept,Sorbonne Paris Cite, Paris, France
[2] CH Blois, Dept Gastroenterol, Blois, France
[3] Versailles St Quentin Univ, CHU St Perine, APHP, Dept Geriatr, Paris, France
[4] FFCD, Dept Stat, Dijon, France
[5] Clin Chenieux, Dept Oncol, Limoges, France
[6] CH Oncogard, Ales, France
[7] CH Meaux, Dept Gastroenterol, Meaux, France
[8] CHU Robert Debre, Dept Gastroenterol, Reims, France
[9] CH Pasteur, Dept Gastroenterol, Colmar, France
[10] Aix Marseille Univ, CHU La Timone, APHM, Digest Oncol & Gastroenterol Dept, Marseille, France
[11] CHU Hop Nord, Dept Gastroenterol, Marseille, France
[12] CH Annecy Genevois, Dept Oncol, Pringy, France
[13] CH Beziers, Dept Gastroenterol, Beziers, France
[14] CHU Trousseau, Dept Gastroenterol, Tours, France
[15] CH Mt De Marsan, Dept Gastroenterol, Mt De Marsan, France
[16] CH la Roche Sur Yon, Dept Gastroenterol, La Roche Sur Yon, France
[17] Sorbonne Univ, CHU Pitie Salpetriere, APHP, UPMC Gastroenterol Dept, Paris, France
[18] CHU Ambroise Pare, APHP, Dept Gastroenterol, Boulogne, France
[19] CH St Jean, Dept Gastroenterol, Perpignan, France
[20] CHU Henri Mondor, APHP, Dept Gastroenterol, Creteil, France
[21] CH Avignon, Dept Oncol, Avignon, France
[22] Inst Curie, Dept Oncol, St Cloud, France
[23] CHU Bocage, Dijon, France
[24] INSERM, U866, Dijon, France
关键词
Colorectal cancer; Elderly; Geriatric assessment; Prognostic factors; Irinotecan; QUALITY-OF-LIFE; OLDER PATIENTS; OPEN-LABEL; TOLERANCE; SURVIVAL; CAPECITABINE; BEVACIZUMAB; COMBINATION; VALIDATION; PREDICTORS;
D O I
10.1016/j.ejca.2016.09.029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: Several predictors of metastatic colorectal cancer (mCRC) outcomes have been described. Specific geriatric characteristics could be of interest to determine prognosis. Method: Elderly patients (75+) with previously untreated mCRC were randomly assigned to receive infusional 5-fluorouracil-based chemotherapy, either alone (FU) or in combination with irinotecan (IRI). Geriatric evaluations were included as an optional procedure. The predictive value of geriatric parameters was determined for the objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). Results: From June 2003 to May 2010, the FFCD 2001-02 randomised trial enrolled 282 patients. A baseline geriatric evaluation was done in 123 patients; 62 allocated to the FU arm and 61 to the IRI arm. The baseline Charlson index was <= 1 in 75%, Mini-Mental State Examination was <= 27/30 in 31%, Geriatric Depression Scale was >2 in 10% and Instrumental Activities of Daily Living (IADL) was impaired in 34% of the patients. Multivariate analyses revealed that no geriatric parameter was predictive for ORR or PFS. Normal IADL was independently associated with better OS. The benefit of doublet chemotherapy on PFS differed in subgroups of patients <= 80 years, with unresected primary tumour, leucocytes >11,000 mm(3) and carcinoembryonic antigen >2N. There was a trend towards better OS in patients with normal IADL. Conclusion: The autonomy score was an independent predictor for OS. A trend toward a better efficacy of doublet chemotherapy in some subgroups of patients was reported and should be further explored. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:98 / 108
页数:11
相关论文
共 32 条
  • [21] HOUSING FOR ELDERLY - A SYMPOSIUM - INTRODUCTION
    LAWTON, MP
    [J]. GERONTOLOGIST, 1969, 9 (01) : 9 - +
  • [22] Accuracy of the G-8 geriatric-oncology screening tool for identifying vulnerable elderly patients with cancer according to tumour site: The ELCAPA-02 study
    Liuu, Evelyne
    Canoui-Poitrine, Florence
    Tournigand, Christophe
    Laurent, Marie
    Caillet, Philippe
    Le Thuaut, Aurelie
    Vincent, Helene
    Culine, Stephane
    Audureau, Etienne
    Bastuji-Garin, Sylvie
    Paillaud, Elena
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2014, 5 (01) : 11 - 19
  • [23] Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy:: A prognostic analysis of the Multicenter Italian Lung Cancer in the Elderly Study
    Maione, P
    Perrone, F
    Gallo, C
    Manzione, L
    Piantedosi, FV
    Barbera, S
    Cigolari, S
    Rosetti, F
    Piazza, E
    Robbiati, SF
    Bertetto, O
    Novello, S
    Migliorino, MR
    Favaretto, A
    Spatafora, M
    Ferraù, F
    Frontini, L
    Bearz, A
    Repetto, L
    Gridelli, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (28) : 6865 - 6872
  • [24] Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013
    Papamichael, D.
    Audisio, R. A.
    Glimelius, B.
    de Gramont, A.
    Glynne-Jones, R.
    Haller, D.
    Koehne, C. -H.
    Rostoft, S.
    Lemmens, V.
    Mitry, E.
    Rutten, H.
    Sargent, D.
    Sastre, J.
    Seymour, M.
    Starling, N.
    Van Cutsem, E.
    Aapro, M.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (03) : 463 - 476
  • [25] Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C
    Price, T. J.
    Zannino, D.
    Wilson, K.
    Simes, R. J.
    Cassidy, J.
    Van Hazel, G. A.
    Robinson, B. A.
    Broad, A.
    Ganju, V.
    Ackland, S. P.
    Tebbutt, N. C.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 (06) : 1531 - 1536
  • [26] Use of Geriatric Assessment for Older Adults in the Oncology Setting: A Systematic Review
    Puts, M. T. E.
    Hardt, J.
    Monette, J.
    Girre, V.
    Springall, E.
    Alibhai, S. M. H.
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (15): : 1133 - 1163
  • [27] Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer:: A Spanish cooperative group for the treatment of digestive tumors study
    Sastre, J
    Marcuello, E
    Masutti, B
    Navarro, M
    Gil, S
    Antón, A
    Abad, A
    Aranda, E
    Maurel, J
    Valladares, M
    Maestu, I
    Carrato, A
    Vicent, JM
    Díaz-Rubio, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) : 3545 - 3551
  • [28] Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
    Seymour, Matthew T.
    Thompson, Lindsay C.
    Wasan, Harpreet S.
    Middleton, Gary
    Brewster, Alison E.
    Shepherd, Stephen F.
    O'Mahony, M. Sinend
    Maughan, Timothy S.
    Parmar, Mahesh
    Langley, Ruth E.
    [J]. LANCET, 2011, 377 (9779) : 1749 - 1759
  • [29] Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer
    Soubeyran, Pierre
    Fonck, Marianne
    Blanc-Bisson, Christele
    Blanc, Jean-Frederic
    Ceccaldi, Joel
    Mertens, Cecile
    Imbert, Yves
    Cany, Laurent
    Vogt, Luc
    Dauba, Jerome
    Andriamampionona, Francis
    Houede, Nadine
    Floquet, Anne
    Chomy, Francois
    Brouste, Veronique
    Ravaud, Alain
    Bellera, Carine
    Rainfray, Muriel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15) : 1829 - 1834
  • [30] Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer: A phase II trial
    Souglakos, J
    Pallis, A
    Kakolyris, S
    Mavroudis, D
    Androulakis, N
    Kouroussis, C
    Agelaki, S
    Xenidis, N
    Milaki, G
    Georgoulias, V
    [J]. ONCOLOGY, 2005, 69 (05) : 384 - 390